Akero Therapeutics (AKRO) stock soared 5.76% in the intraday trading session on Thursday, following an analyst upgrade and a bullish price target revision.
BofA Securities upgraded Akero Therapeutics to a "Buy" rating from "Neutral" and raised its price target to $63, implying significant upside potential from the current levels. The bullish stance from the analysts fueled optimism among investors, driving the stock higher.
According to analysts polled by FactSet, Akero Therapeutics currently has an average rating of "Buy" and a mean price target of $72.18, suggesting further upside potential for the stock based on analysts' expectations.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。